Michael Arad

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8963796/publications.pdf

Version: 2024-02-01

83	5,233	136885	88593
papers	citations	32 h-index	70 g-index

86	86	86	6289
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Glycogen Storage Diseases Presenting as Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2005, 352, 362-372.	13.9	573
2	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	1.0	434
3	Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. Journal of Clinical Investigation, 2002, 109, 357-362.	3.9	389
4	Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. Journal of the American College of Cardiology, 2016, 68, 2440-2451.	1.2	340
5	AMP-Activated Protein Kinase in the Heart. Circulation Research, 2007, 100, 474-488.	2.0	311
6	Clinical Outcome and Phenotypic Expression in <emph type="ital">LAMP2</emph> Cardiomyopathy. JAMA - Journal of the American Medical Association, 2009, 301, 1253.	3.8	297
7	Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. Journal of Clinical Investigation, 2002, 109, 357-362.	3.9	228
8	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576.	2.9	224
9	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. European Heart Journal, 2017, 38, 2649-2662.	1.0	163
10	Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. Journal of Clinical Investigation, 2007, 117, 1814-1823.	3.9	158
11	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	2.9	153
12	Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving â€˜SIRT1 and PGC-1Î±â€™. Cardiovascular Diabetology, 2018, 17, 111.	2.7	128
13	European expert consensus statement on therapeutic goals in Fabry disease. Molecular Genetics and Metabolism, 2018, 124, 189-203.	0.5	122
14	Limb ischemia preconditions the heart against reperfusion tachyarrhythmia. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 273, H1707-H1712.	1.5	96
15	Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. Journal of Clinical Investigation, 2007, 117, 1432-1439.	3.9	95
16	Reversibility of PRKAG2 Glycogen-Storage Cardiomyopathy and Electrophysiological Manifestations. Circulation, 2008, 117, 144-154.	1.6	78
17	Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: Results of a structured exercise training program in a cardiac rehabilitation center. European Journal of Preventive Cardiology, 2015, 22, 13-19.	0.8	74
18	Functional abnormalities in iPSCâ€derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations. Journal of Cellular and Molecular Medicine, 2015, 19, 2006-2018.	1.6	73

#	Article	IF	Citations
19	The role of 20-HETE in cardiovascular diseases and its risk factors. Prostaglandins and Other Lipid Mediators, 2016, 125, 108-117.	1.0	68
20	Epoxyeicosatrienoic Acids Regulate Adipocyte Differentiation of Mouse 3T3 Cells, Via PGC-1Î± Activation, Which Is Required for HO-1 Expression and Increased Mitochondrial Function. Stem Cells and Development, 2016, 25, 1084-1094.	1.1	67
21	The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease â€“ A systematic literature review by a European panel of experts. Molecular Genetics and Metabolism, 2019, 126, 224-235.	0.5	65
22	Phenotype and prognostic correlations of the converter region mutations affecting the Î² myosin heavy chain. Heart, 2015, 101, 1047-1053.	1.2	54
23	CRISPR correction of the PRKAG2 gene mutation in the patient's induced pluripotent stem cell-derived cardiomyocytes eliminates electrophysiological and structural abnormalities. Heart Rhythm, 2018, 15, 267-276.	0.3	54
24	PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1Î± axis. Experimental Cell Research, 2018, 373, 112-118.	1.2	52
25	Clinical Experience With Deferiprone Treatment for Friedreich Ataxia. Journal of Child Neurology, 2016, 31, 1036-1040.	0.7	45
26	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. Journal of the American College of Cardiology, 2020, 76, 186-197.	1.2	45
27	Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice. Heart Rhythm, 2010, 7, 1676-1682.	0.3	44
28	Electrophysiological abnormalities in induced pluripotent stem cellâ€derived cardiomyocytes generated from Duchenne muscular dystrophy patients. Journal of Cellular and Molecular Medicine, 2019, 23, 2125-2135.	1.6	39
29	Functional abnormalities in induced Pluripotent Stem Cell-derived cardiomyocytes generated from titin-mutated patients with dilated cardiomyopathy. PLoS ONE, 2018, 13, e0205719.	1.1	38
30	The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy. European Heart Journal, 2019, 40, 1671-1677.	1.0	37
31	<scp>SK</scp> 4 K ⁺ channels are therapeutic targets for the treatment of cardiac arrhythmias. EMBO Molecular Medicine, 2017, 9, 415-429.	3.3	36
32	Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models. Heart Rhythm, 2017, 14, 1053-1060.	0.3	34
33	Angiogenic Imbalance and Residual Myocardial Injury in Recovered Peripartum Cardiomyopathy Patients. Circulation: Heart Failure, 2016, 9, .	1.6	32
34	Differences in Mortality of New-Onset (De-Novo) Acute Heart Failure Versus Acute Decompensated Chronic Heart Failure. American Journal of Cardiology, 2019, 124, 554-559.	0.7	31
35	Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during longâ€term followâ€up. Clinical Transplantation, 2017, 31, e13133.	0.8	30
36	Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system. Cardiovascular Diabetology, 2021, 20, 90.	2.7	30

#	Article	IF	Citations
37	Clinical Profile of Cardiac Involvement in Danon Disease. Circulation Genomic and Precision Medicine, 2020, 13, e003117.	1.6	29
38	TLR4 Expression Is Associated with Left Ventricular Dysfunction in Patients Undergoing Coronary Artery Bypass Surgery. PLoS ONE, 2015, 10, e0120175.	1.1	27
39	Caloric restriction ameliorates cardiomyopathy in animal model of diabetes. Experimental Cell Research, 2017, 350, 147-153.	1.2	25
40	Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm, 2011, 8, 1546-1552.	0.3	22
41	Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice. Heart Rhythm, 2014, 11, 1471-1479.	0.3	22
42	Psychiatric and cognitive characteristics of individuals with Danon disease (LAMP2 gene) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54	0.7	22
43	The Role of Heme Oxygenase 1 in the Protective Effect of Caloric Restriction against Diabetic Cardiomyopathy. International Journal of Molecular Sciences, 2019, 20, 2427.	1.8	22
44	Exercise training in advanced heart failure patients: Discordance between improved exercise tolerance and unchanged NT-proBNP levels. International Journal of Cardiology, 2008, 126, 114-119.	0.8	18
45	Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study. Targeted Oncology, 2021, 16, 471-483.	1.7	17
46	Effects of Heat-Exercise Stress, NBC Clothing, and Pyridostigmine Treatment on Psychomotor and Subjective Measures of Performance. Military Medicine, 1992, 157, 210-214.	0.4	16
47	Inherited cardiomyopathiesâ€"Novel therapies. , 2015, 155, 36-48.		14
48	Metformin therapy reduces the risk of malignancy after heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 1350-1357.	0.3	14
49	Prevalence and clinical outcomes of dystrophinâ€associated dilated cardiomyopathy without severe skeletal myopathy. European Journal of Heart Failure, 2021, 23, 1276-1286.	2.9	14
50	SNTA1 gene rescues ion channel function and is antiarrhythmic in cardiomyocytes derived from induced pluripotent stem cells from muscular dystrophy patients. ELife, 0, 11, .	2.8	14
51	Sex-Based Differences in Characteristics and In-Hospital Outcomes among Patients With Diagnosed Acute Myocarditis. American Journal of Cardiology, 2020, 125, 1694-1699.	0.7	12
52	Protaglandins and the antiarrhythmic effect of preconditioning in the isolated rat heart. Molecular and Cellular Biochemistry, 1996, 160-161, 249-255.	1.4	11
53	Generation of Duchenne muscular dystrophy patient-specific induced pluripotent stem cell line lacking exons 45â€"50 of the dystrophin gene (IITi001-A). Stem Cell Research, 2018, 29, 111-114.	0.3	11
54	Donor thyroid hormone therapy is associated with an increased risk of graft dysfunction after heart transplantation. Clinical Transplantation, 2020, 34, e13887.	0.8	11

#	Article	IF	Citations
55	Reduction in Filamin C transcript is associated with arrhythmogenic cardiomyopathy in Ashkenazi Jews. International Journal of Cardiology, 2020, 317, 133-138.	0.8	11
56	Inflammatory Biomarkers in Refractory Congestive Heart Failure Patients Treated with Peritoneal Dialysis. BioMed Research International, 2015, 2015, 1-8.	0.9	10
57	Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathway. Prostaglandins and Other Lipid Mediators, 2020, 150, 106454.	1.0	10
58	The Peroxisome Proliferator-Activated Receptor-Gamma Coactivator-1Î±â€“Heme Oxygenase 1 Axis, a Powerful Antioxidative Pathway with Potential to Attenuate Diabetic Cardiomyopathy. Antioxidants and Redox Signaling, 2020, 32, 1273-1290.	2.5	10
59	LAMP2 Cardiomyopathy: Consequences of Impaired Autophagy in the Heart. Journal of the American Heart Association, 2021, 10, e018829.	1.6	10
60	Modeling Peripartum Cardiomyopathy With Human Induced Pluripotent Stem Cells Reveals Distinctive Abnormal Function of Cardiomyocytes. Circulation, 2018, 138, 2721-2723.	1.6	9
61	A Family with Recurrent Sudden Death and No Clinical Clue. Annals of Noninvasive Electrocardiology, 2012, 17, 387-393.	0.5	8
62	Cardiac Danon disease: Insights and challenges. International Journal of Cardiology, 2017, 245, 211-212.	0.8	7
63	Risk of early, intermediate, and late rejection following heart transplantation: Trends over the past 25Âyears and relation to changes in medical management. Tertiary center experience: The Sheba Heart Transplantation Registry. Clinical Transplantation, 2017, 31, e13063.	0.8	7
64	The Hyperpolarization-Activated Cyclic-Nucleotide-Gated Channel Blocker Ivabradine Does Not Prevent Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia. Frontiers in Pharmacology, 2019, 10, 1566.	1.6	7
65	Investigating LMNA-Related Dilated Cardiomyopathy Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. International Journal of Molecular Sciences, 2021, 22, 7874.	1.8	7
66	Efficacy and safety of exercise rehabilitation in patients with hypertrophic cardiomyopathy. Journal of Cardiology, 2019, 74, 466-472.	0.8	6
67	Molecular adaptation to calsequestrin 2 (CASQ2) point mutations leading to catecholaminergic polymorphic ventricular tachycardia (CPVT): comparative analysis of R33Q and D307H mutants. Journal of Muscle Research and Cell Motility, 2020, 41, 251-258.	0.9	6
68	Depressed Î²â€adrenergic inotropic responsiveness and intracellular calcium handling abnormalities in Duchenne Muscular Dystrophy patientsâ€™ induced pluripotent stem cellâ€“derived cardiomyocytes. Journal of Cellular and Molecular Medicine, 2021, 25, 3922-3934.	1.6	6
69	Ethnic Differences Among Implantable Cardioverter Defibrillators Recipients in Israel. American Journal of Cardiology, 2015, 115, 1102-1106.	0.7	4
70	New Insights on Genetic Diagnostics in Cardiomyopathy and Arrhythmia Patients Gained by Stepwise Exome Data Analysis. Journal of Clinical Medicine, 2020, 9, 2168.	1.0	4
71	Sex Differences in Clinical Characteristics and 1- and 10-Year Mortality Among Patients Hospitalized With Acute Heart Failure. American Journal of the Medical Sciences, 2020, 360, 392-401.	0.4	4
72	Merits and pitfalls of genetic testing in a hypertrophic cardiomyopathy clinic. Israel Medical Association Journal, 2014, 16, 707-13.	0.1	4

#	Article	IF	Citations
73	De novo mitral regurgitation as a cause of heart failure exacerbation in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2018, 252, 122-127.	0.8	3
74	Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis. ESC Heart Failure, 2022, , .	1.4	3
75	Peptide-based development of PKA activators. New Journal of Chemistry, 2018, 42, 18585-18597.	1.4	2
76	Genetic ideology of dilated cardiompathy. Israel Medical Association Journal, 2005, 7, 392-6.	0.1	2
77	Blood pressure dynamics during exercise rehabilitation in heart failure patients. European Journal of Preventive Cardiology, 2017, 24, 818-824.	0.8	1
78	Multi-system neurological disorder associated with a CRYAB variant. Neurogenetics, 2021, 22, 117-125.	0.7	1
79	The Late Effects of Pregnancy on Aortic Dimensions in Patients with Marfan Syndrome. Cardiology, 2021, 146, 98-105.	0.6	1
80	Response by Naftali-Shani et al to Letter Regarding Article, â€œModeling Peripartum Cardiomyopathy With Human Induced Pluripotent Stem Cells Reveals Distinctive Abnormal Function of Cardiomyocytesâ€• Circulation, 2019, 139, e992-e993.	1.6	0
81	Pseudo-discordance mimicking low-flow low-gradient aortic stenosis in transcatheter aortic valve replacement patients with severe symptomatic aortic stenosis. Cardiology Journal, 2021, , .	0.5	0
82	Sub-acute vs. Late-onset Presentation of Oncotherapy Related Cardiotoxicity: Predictors of Cardiac Function Recovery and Long-Term Outcome. Israel Medical Association Journal, 2018, 20, 486-490.	0.1	0
83	Anesthesia in Parturients Presenting with Marfan Syndrome. Israel Medical Association Journal, 2021, 23, 437-440.	0.1	0